MBX Biosciences, Inc. (NYSE:MBX - Get Free Report) Director Carl L. Gordon purchased 47,502 shares of the business's stock in a transaction that occurred on Friday, February 14th. The stock was acquired at an average price of $9.87 per share, for a total transaction of $468,844.74. Following the purchase, the director now owns 3,205,930 shares of the company's stock, valued at approximately $31,642,529.10. This represents a 1.50 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
MBX Biosciences Trading Up 2.9 %
Shares of MBX opened at $11.22 on Thursday. The firm has a 50 day simple moving average of $14.22. MBX Biosciences, Inc. has a 52-week low of $8.63 and a 52-week high of $27.50.
Institutional Trading of MBX Biosciences
Institutional investors have recently added to or reduced their stakes in the stock. Teachers Retirement System of The State of Kentucky acquired a new stake in MBX Biosciences in the third quarter valued at $694,000. Barclays PLC bought a new stake in MBX Biosciences in the third quarter valued at about $426,000. NEA Management Company LLC acquired a new stake in MBX Biosciences during the third quarter valued at approximately $93,904,000. Geode Capital Management LLC acquired a new stake in MBX Biosciences during the third quarter valued at approximately $579,000. Finally, The Manufacturers Life Insurance Company bought a new position in MBX Biosciences during the 3rd quarter worth approximately $1,200,000.
MBX Biosciences Company Profile
(
Get Free Report)
MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
